potential once-monthly injectable GLP-1 RA engineered with Metsera’s HALO™ lipidation platform. MET-097i showed a 7.5% reduction in body weight from baseline at day 36 and a 380-hour half-life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback